CureVac (CVAC) Price & Analysis

Compare

1,258 Followers

CVAC Stock Chart & Stats

$5.48

-$0.57(-12.18%)

At close: Jan 08 4:00 PM EST

$5.48

-$0.57(-12.18%)

Day’s Range― - ―

52-Week Range$2.48 - $5.72

Previous CloseN/A

Volume1.54M

Average Volume (3M)873.45K

Market Cap

$1.24B

Enterprise Value$769.41M

Total Cash (Recent Filing)$395.81M

Total Debt (Recent Filing)$36.03M

Price to Earnings (P/E)7.6

Beta1.20

Next Earnings

Apr 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding225,181,640

10 Day Avg. Volume1,435,350

30 Day Avg. Volume873,446

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)1.06

Price to Sales (P/S)1.38

P/FCF Ratio8.86

Enterprise Value/Market Cap0.62

Enterprise Value/Revenue1.51

Enterprise Value/Gross Profit1.59

Enterprise Value/Ebitda3.22

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.52

Revenue Forecast (FY)$72.34M

Bulls Say, Bears Say

Bulls Say

AcquisitionBNTX announced an all-stock acquisition offer for CVAC for ~$1.25B, with CVAC shares exchanged for $5.46 in BNTX ADS – a ~55% premium to CVAC’s trailing 3-month average price.

Financial PositionCVAC ended the period with €392.7mm in cash and equivalents, expected to fund operations into 2028.

Bears Say

Market UncertaintyThere is uncertainty in the respiratory vaccine franchise, partnered with GSK, as the COVID market wanes.

Operating LossOperating loss of €61.7mm was above consensus expectations.

CureVac News

BioNTech shares update on exchange offer for CureVac shares

BioNTech (BNTX) announced the approval of matters relating to the exchange offer for all outstanding shares of CureVac...

5d ago

BNTX

CVAC

Midday Fly By: Novo Alzheimer’s trial misses goal, Green Dot to be acquired

The major averages were broadly higher near noon as the markets aim to rebound heading into the Thanksgiving...

7d ago

CureVac reports Q3 revenue EUR 54.1M vs. EUR 493.9M last year

“This quarter, we have made continued progress toward completing the planned transaction with BioNTech, bringing us closer to...

7d ago

CVAC

CureVac reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year

07:50 EST CureVac (CVAC) reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year Published first on TheFly...

7d ago

CVAC

CureVac sees cash runway into 2028

Cash and cash equivalents totaled EUR 416.1 million as of September 30, 2025, compared with EUR 481.7 million...

7d ago

CVAC

CureVac Shareholders Approve BioNTech Exchange Offer

CureVac ( ($CVAC) ) just unveiled an announcement. On November 25, 2025, CureVac N.V. announced the results of...

5d ago

CVAC

CureVac Reports Q3 2025 Financial Results and Updates

Curevac N.V. ( ($CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac...

6d ago

CVAC

CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress

The latest announcement is out from CureVac ( ($CVAC) ). On November 24, 2025, CureVac N.V. announced its...

7d ago

CVAC

CVAC Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Curevac N.V. (CVAC) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street analysts...

15d ago

CVAC

CureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer Treatment

Curevac N.V. (($CVAC)) announced an update on their ongoing clinical study. Study Overview: CureVac N.V. is conducting a...

1M ago

CVAC

CureVac Announces Extraordinary Meeting for Merger with BioNTech

An update from CureVac ( ($CVAC) ) is now available. On October 24, 2025, CureVac N.V. announced an...

1M ago

CVAC

BioNTech commences public exchange offer for CureVac shares

BioNTech (BNTX) announced it had commenced its public exchange offer for all outstanding shares of CureVac (CVAC). The...

1M ago

BNTX

CVAC

CureVac’s Strategic Moves and Financial Highlights in 2025

Curevac N.V. ( ($CVAC) ) has released its Q2 earnings. Here is a breakdown of the information Curevac...

3M ago

CVAC

CureVac Reports Financial Losses in Mid-2025

CureVac ( ($CVAC) ) has issued an update. CureVac N.V. released its unaudited interim condensed consolidated financial statements...

4M ago

CVAC

CVAC FAQ

What was Curevac N.V.’s price range in the past 12 months?

Curevac N.V. lowest stock price was $2.48 and its highest was $5.72 in the past 12 months.

What is Curevac N.V.’s market cap?

Curevac N.V.’s market cap is $1.24B.

When is Curevac N.V.’s upcoming earnings report date?

Curevac N.V.’s upcoming earnings report date is Apr 29, 2026 which is in 149 days.

How were Curevac N.V.’s earnings last quarter?

Curevac N.V. released its earnings results on Nov 24, 2025. The company reported -$0.081 earnings per share for the quarter, the consensus estimate of -$0.081 by $0.

Is Curevac N.V. overvalued?

According to Wall Street analysts Curevac N.V.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Curevac N.V. pay dividends?

Curevac N.V. does not currently pay dividends.

What is Curevac N.V.’s EPS estimate?

Curevac N.V.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Curevac N.V. have?

Curevac N.V. has 225,181,640 shares outstanding.

What happened to Curevac N.V.’s price movement after its last earnings report?

Curevac N.V. reported an EPS of -$0.081 in its last earnings report, expectations of -$0.081. Following the earnings report the stock price went up 1.59%.

Which hedge fund is a major shareholder of Curevac N.V.?

Currently, no hedge funds are holding shares in CVAC

CureVac Stock Smart Score

Outperform

Fundamentals

Return on Equity

17.68%

Trailing 12-Months

Asset Growth

40.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Curevac N.V.

CureVac (CVAC) is a biopharmaceutical company that specializes in the development of mRNA-based therapies and vaccines. Founded in Germany, the company aims to harness the power of messenger RNA to treat various diseases, including infectious diseases, cancer, and rare diseases. CureVac is at the forefront of the mRNA technology sector, focusing on creating innovative solutions that can potentially transform the landscape of medicine and immunotherapy.